FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
Professor and Chief, Pediatric Nephrology and Hypertension, Jack and Lucy Clark Department of Pediatrics, Mount Sinai Kravis Children’s Hospital, New York City and Investigator on the ILLUMINATE-A trial. 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Saland, M.D., 2Near-normal is defined as urinary oxalate levels at or below 1.5
52 
Let's personalize your content